Gimv
Hard times over for hardware investments?
The hardware end of Europe’s technology market has largely been ignored by GPs in favour of the safety net of software. Ellie Pullen investigates the reasons behind its neglect and whether the sector is about to become a more appealing investment opportunity...
Gimv fully exits Ablynx
Gimv has sold its remaining direct stake of 2.24% in Euronext-listed Ablynx, a Belgian biotechnology company, for €19.1m.
NovoPolymers pulls in further VC funding
Gimv, Capricorn Venture Partners and the Federale Participatie- en Investeringsmaatschappij (SFPI-FPIM) have reinvested in Belgian solar encapsulant manufacturer NovoPolymers alongside new backer Capital-E.
Sector focus: An outbreak of biotech IPOs
Biotech IPOs
St Jude Medical acquires PE-backed Endosense
Medical device company St Jude Medical has wholly acquired Endosense, a medical technology company backed by several private equity firms, for CHF 159m.
Benelux exit market lifts
Benelux
Gimv et al. back Jenavalve
A consortium of venture capital investors has injected $62.5m as part of a series-C round for Jenavalve Technology, a Germany-based medical devices manufacturer.
Gimv and Bencis pinch Punch's Xeikon
Gimv and Bencis Capital Partners have acquired a stake in listed Dutch printing business Xeikon from parent company Punch International.
VC-backed Prosensa raises $78m in IPO
Dutch biotechnology company Prosensa Holding, which is backed by a consortium of venture capital firms, has listed on the Nasdaq Global Select Market in an IPO valuing the business at $408m.
Gimv and EdRip back Complix with €12m
Gimv and Edmond de Rothschild Investment Partners (EdRip) have led a €12m series-B round for Belgian biopharmaceutical company Complix.
Gimv backs MBO of Luciad
Gimv has acquired a majority stake in Luciad, a Belgian supplier of situational awareness systems-building software, alongside the company’s management.
Gimv and Iris invest €15m in Alven-backed Planetveo
Gimv and Iris Capital have invested €15m in French online travel agency Planetveo, which has previously received backing from Alven Capital.
Gimv backs €40m investment in Lampiris
Gimv has jointly invested €40m in Belgian green energy supplier Lampiris with the Regional Investment Company of Wallonia (SRIW).
Gimv makes 1.3x return on divestments for 2012/13
Gimv has announced a 1.3x return on divestments, relative to original acquisition value, for the year ending in March 2013.
Gimv sells stake in Halder
Belgian private equity firm Gimv has handed back its stake in fellow German private equity house Halder to the GP.
Gimv's Verbinnen winds up
Gimv-backed Belgian food processing business Verbinnen Poultry Group has filed a petition to wind up on 25 February 2013 after failing to find a buyer.
Gimv launches Health & Care Fund
Gimv has launched a new €200m fund focused on healthcare and medical technology investments.
Gimv et al. invest €5.5m in pharma company Multiplicom
Gimv and regional Belgian players have invested €5.5m in Antwerp-based biotechnology company Multiplicom NV.
CDC leads €10m round for McPhy Energy
CDC Entreprises has invested €5m as part of a €10m round for French hydrogen storage specialist McPhy Energy.
Gimv et al. invest €5m in biotech startup AgroSavfe
Gimv has led a €5m investment in Belgian green crop protection products business AgroSavfe, alongside regional funds PMV, Sofi, QBIC and VIB.
Gimv buys ProxiAD from UI Gestion
Gimv has acquired a majority stake in French software engineering services provider ProxiAD from UI Gestion.
Gimv takes loss on Salsa Food Group
Gimv has sold its shares in Belgian ready-made salad company Salsa Food Group to private equity-backed SaladSignature, a producer of refrigerated spreadable salads and convenience food.
Gimv and Iris Capital sell stake in Human Inference
Gimv and Iris Capital have sold their share of Dutch data management solutions provider Human Inference to French trade buyer Neopost.
Gimv sells Mentum to InfoVista
Gimv has sold its stake in French software provider Mentum to network solutions company InfoVista after a 10-year holding period.